Naim Alkhouri
#165,696
Most Influential Person Now
Researcher
Naim Alkhouri's AcademicInfluence.com Rankings
Naim Alkhouriengineering Degrees
Engineering
#7322
World Rank
#8689
Historical Rank
Electrical Engineering
#2274
World Rank
#2380
Historical Rank
Naim Alkhouricomputer-science Degrees
Computer Science
#9909
World Rank
#10395
Historical Rank
Computational Linguistics
#2460
World Rank
#2484
Historical Rank
Machine Learning
#4463
World Rank
#4513
Historical Rank
Artificial Intelligence
#4821
World Rank
#4884
Historical Rank
Download Badge
Engineering Computer Science
Naim Alkhouri's Degrees
- PhD Computer Science Stanford University
Similar Degrees You Can Earn
Why Is Naim Alkhouri Influential?
(Suggest an Edit or Addition)Naim Alkhouri's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal (2009) (351)
- NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances (2018) (325)
- Adipocyte Apoptosis, a Link between Obesity, Insulin Resistance, and Hepatic Steatosis* (2009) (304)
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial (2019) (262)
- Ultrasonographic Quantitative Estimation of Hepatic Steatosis in Children With NAFLD (2011) (227)
- Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease (2012) (223)
- Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials. (2020) (214)
- Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications (2011) (193)
- An apoptosis panel for nonalcoholic steatohepatitis diagnosis. (2011) (169)
- Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data (2017) (167)
- Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials (2019) (158)
- Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. (2020) (153)
- NAFLD in children: new genes, new diagnostic modalities and new drugs (2019) (148)
- Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis With Cirrhosis And Portal Hypertension. (2019) (148)
- Nonalcoholic fatty liver disease: a challenge for pediatricians. (2015) (138)
- A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. (2021) (137)
- Acetyl‐CoA Carboxylase Inhibitor GS‐0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis (2018) (135)
- Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis (2016) (130)
- Serum Cytokeratin-18 Fragment Levels Are Useful Biomarkers for Nonalcoholic Steatohepatitis in Children (2013) (113)
- Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH (2020) (107)
- Therapeutic pipeline in nonalcoholic steatohepatitis (2021) (105)
- Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic (2017) (105)
- TEMPORARY REMOVAL: Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. (2019) (100)
- Receptor interacting protein 3 protects mice from high‐fat diet‐induced liver injury (2016) (99)
- The Inflamed Liver and Atherosclerosis: A Link Between Histologic Severity of Nonalcoholic Fatty Liver Disease and Increased Cardiovascular Risk (2010) (97)
- Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in Young Adults in the United States (2017) (93)
- The breathprints in patients with liver disease identify novel breath biomarkers in alcoholic hepatitis. (2014) (92)
- A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. (2011) (89)
- Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease (2013) (86)
- Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities. (2014) (84)
- Analysis of breath volatile organic compounds as a noninvasive tool to diagnose nonalcoholic fatty liver disease in children (2014) (78)
- Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD. (2012) (76)
- Hepatitis B Immunity and Response to Booster Vaccination in Children With Inflammatory Bowel Disease Treated With Infliximab (2012) (74)
- Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. (2019) (74)
- Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. (2021) (74)
- Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. (2009) (72)
- Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. (2021) (72)
- Metabolomic analysis of breath volatile organic compounds reveals unique breathprints in children with inflammatory bowel disease: a pilot study (2014) (72)
- Severity of Liver Injury and Atherogenic Lipid Profile in Children With Nonalcoholic Fatty Liver Disease (2010) (70)
- The Evaluation of Hepatic Fibrosis Scores in Children with Nonalcoholic Fatty Liver Disease (2013) (70)
- Serum Retinol-binding Protein 4 Levels in Patients With Nonalcoholic Fatty Liver Disease (2009) (68)
- GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH) (2020) (66)
- The Development of the Pediatric NAFLD Fibrosis Score (PNFS) to Predict the Presence of Advanced Fibrosis in Children with Nonalcoholic Fatty Liver Disease (2014) (65)
- Isoprene in the Exhaled Breath is a Novel Biomarker for Advanced Fibrosis in Patients with Chronic Liver Disease: A Pilot Study (2015) (64)
- Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease. (2012) (62)
- Increasing Burden of Chronic Liver Disease Among Adolescents and Young Adults in the USA: A Silent Epidemic (2017) (60)
- Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. (2021) (59)
- Relations of Steatosis Type, Grade, and Zonality to Histological Features in Pediatric Nonalcoholic Fatty Liver Disease (2011) (58)
- Autoimmune hepatitis in children--impact of cirrhosis at presentation on natural history and long-term outcome. (2010) (58)
- Changes in body composition after transjugular intrahepatic portosystemic stent in cirrhosis: a critical review of literature (2011) (57)
- Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. (2016) (57)
- Liver transplantation for nonalcoholic steatohepatitis in young patients (2016) (56)
- Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet? (2016) (54)
- Review article: breath analysis in inflammatory bowel diseases (2015) (54)
- Sofosbuvir‐based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series (2016) (53)
- Stearoyl-CoA desaturase plays an important role in proliferation and chemoresistance in human hepatocellular carcinoma. (2014) (53)
- A Comprehensive Review of Noninvasive Liver Fibrosis Tests in Pediatric Nonalcoholic Fatty Liver Disease (2015) (53)
- Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand? (2020) (51)
- Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices (2020) (48)
- Screening for Non-Alcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the U.S. is Cost Effective: A Comprehensive Cost-Utility Analysis. (2020) (48)
- Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm? (2019) (46)
- Serum Bilirubin Level Is Inversely Associated With Nonalcoholic Steatohepatitis in Children (2013) (46)
- Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease. (2009) (43)
- Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic. (2019) (42)
- Breathprints of childhood obesity: changes in volatile organic compounds in obese children compared with lean controls (2015) (42)
- OxNASH Score Correlates with Histologic Features and Severity of Nonalcoholic Fatty Liver Disease (2011) (41)
- Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. (2020) (40)
- Mean platelet volume as a marker of increased cardiovascular risk in patients with nonalcoholic steatohepatitis (2012) (39)
- Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH (2021) (37)
- Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease (2016) (36)
- Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease (2011) (35)
- Presence of sarcopenia (muscle wasting) in patients with nonalcoholic steatohepatitis (2014) (35)
- Plant-Based No Added Fat or American Heart Association Diets, Impact on Cardiovascular Risk in Obese Hypercholesterolemic Children and Their Parents (2015) (35)
- MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study (2018) (35)
- Health-Related Quality of Life in Children With Autoimmune Liver Disease (2013) (33)
- Prevalence of Suspected Nonalcoholic Fatty Liver Disease in Lean Adolescents in the United States (2018) (32)
- MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. (2021) (31)
- Nonalcoholic Fatty Liver Disease in Children: Hepatic and Extrahepatic Complications. (2017) (31)
- MR elastography‐based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study (2020) (31)
- Analysis of breath volatile organic compounds in children with chronic liver disease compared to healthy controls (2015) (29)
- Johanson-Blizzard syndrome with mild phenotypic features confirmed by UBR1 gene testing. (2008) (29)
- Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. (2022) (29)
- Alpha-1 antitrypsin deficiency and the risk of hepatocellular carcinoma in end-stage liver disease. (2015) (29)
- An update on the pharmacological treatment of nonalcoholic fatty liver disease: Beyond lifestyle modifications (2018) (29)
- Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes (2018) (28)
- The increasing burden of nonalcoholic fatty liver disease among young adults in the United States: A growing epidemic (2016) (28)
- Familial Adenomatous Polyposis in Children and Adolescents (2010) (28)
- The Utility of Noninvasive Scores in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Type 2 Diabetic Patients (2017) (28)
- Non-high-density lipoprotein cholesterol (non-HDL-C) levels in children with nonalcoholic fatty liver disease (NAFLD) (2014) (26)
- A non-invasive prediction model for non-alcoholic steatohepatitis in paediatric patients with non-alcoholic fatty liver disease. (2014) (25)
- A Distinct Colon-Derived Breath Metabolome is Associated with Inflammatory Bowel Disease, but not its Complications (2016) (24)
- Reduced lysosomal acid lipase activity - A potential role in the pathogenesis of non alcoholic fatty liver disease in pediatric patients. (2016) (24)
- Protease inhibitors: Silver bullets for chronic hepatitis C infection? (2012) (24)
- Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease (2020) (23)
- Awareness of Nonalcoholic Fatty Liver Disease Is Increasing but Remains Very Low in a Representative US Cohort (2019) (23)
- Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis (2018) (23)
- Incidence of Complications from Percutaneous Biopsy in Chronic Liver Disease: A Systematic Review and Meta-Analysis (2021) (22)
- Overview of Updated Practice Guidelines for Pediatric Nonalcoholic Fatty Liver Disease. (2018) (22)
- Sofosbuvir/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation: Two-Center Experience (2017) (22)
- Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)? (2020) (21)
- Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic Steatohepatitis (2015) (21)
- Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter (2018) (21)
- Monitoring peripheral blood CD4+ Adenosine triphosphate activity in recurrent hepatitis C and its correlation to fibrosis progression (2010) (21)
- Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two‐center experience (2016) (20)
- Short Bowel Syndrome in Children (2012) (20)
- New insights into genetic predisposition and novel therapeutic targets for nonalcoholic fatty liver disease. (2018) (20)
- Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation (2016) (19)
- Novel therapeutic targets for nonalcoholic fatty liver disease (2013) (19)
- Nonalcoholic fatty liver disease in children: recent practice guidelines, where do they take us? (2014) (19)
- The use of tacrolimus in refractory autoimmune hepatitis in children and adults: a single center experience (2017) (18)
- Evaluation of circulating markers of hepatic apoptosis and inflammation in obese children with and without obstructive sleep apnea. (2015) (17)
- Novel treatments for chronic hepatitis C: closing the remaining gaps. (2017) (17)
- Nonalcoholic fatty liver disease and hepatocellular carcinoma: new insights on presentation and natural history. (2017) (16)
- Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH Treatment (2019) (15)
- Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (2021) (15)
- Three-dimensional printing and pediatric liver disease (2016) (15)
- The TONIC trial: A step forward in treating pediatric nonalcoholic fatty liver disease (2012) (15)
- Portal Hypertension Complications Are Frequently the First Presentation of NAFLD in Patients Undergoing Liver Transplantation Evaluation (2016) (15)
- Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. (2021) (15)
- The Protein-Sparing Modified Fast Diet (2016) (14)
- The search for noninvasive methods to identify liver fibrosis in children with nonalcoholic fatty liver disease. (2018) (14)
- Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients with Hepatocellular Carcinoma. (2020) (14)
- The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients (2018) (13)
- Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort (2019) (13)
- The development of a non‐invasive model to predict the presence of non‐alcoholic steatohepatitis in patients with non‐alcoholic fatty liver disease (2016) (13)
- Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. (2020) (13)
- Comparison between non-alcoholic fatty liver disease screening guidelines in children and adolescents (2019) (13)
- Long-term management of liver transplant recipients: A review for the internist (2015) (13)
- What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond? (2021) (13)
- Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance (2019) (13)
- Ileoscopy via Stoma After Diverting Ileostomy: A Safe and Effective Tool to Evaluate for Crohn’s Recurrence of Neoterminal Ileum (2011) (12)
- Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017–2018 transient elastography data and application of machine learning (2022) (12)
- Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies (2020) (12)
- Norovirus and severe chronic gastroenteritis in pediatric stem cell transplantation: The plot thickens (2011) (12)
- Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis (2018) (12)
- Population-Based Trends in Prevalence of Nonalcoholic Fatty Liver Disease in U.S. Adults With Type 2 Diabetes. (2019) (11)
- Response to hepatitis A vaccine in children with inflammatory bowel disease receiving infliximab. (2011) (11)
- Clinical Practice Approach to Nonalcoholic Fatty Liver Disease by Pediatric Gastroenterologists in the United States (2019) (11)
- Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. (2022) (11)
- Cardiovascular risk factors and cardiac disorders in long‐term survivors of pediatric liver transplantation (2015) (11)
- Driving NASH forward using the FAST score but obey the traffic lights. (2020) (10)
- Increased Prevalence of Obesity and Metabolic Syndrome in Patients with Alcoholic Fatty Liver Disease (2018) (10)
- Reversal of protein‐losing enteropathy after liver transplantation in a child with idiopathic familial neonatal hepatitis (2009) (10)
- Pyostomatitis vegetans as an oral manifestation of Crohn's disease in a pediatric patient. (2010) (10)
- A guide to managing acute liver failure (2016) (10)
- Trends in pioglitazone use among U.S. adults with type 2 diabetes and suspected nonalcoholic fatty liver disease (2019) (10)
- Noninvasive Testing Using Magnetic Resonance Imaging Techniques as Outcomes in Nonalcoholic Steatohepatitis Clinical Trials: How Full Is the Glass? (2020) (9)
- NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges (2020) (9)
- Low Serum Potassium Levels Associated with Disease Severity in Children with Nonalcoholic Fatty Liver Disease (2015) (8)
- Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists (2020) (8)
- Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196) (2019) (8)
- A122: Metabolomic Analysis of Breath Volatile Organic Compounds Reveals Unique Breathprints in Children With Juvenile Idiopathic Arthritis (2014) (8)
- 704 Development and Validation of a New Histological Score for Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) (2012) (8)
- Low-dose naltrexone for treatment of duodenal Crohn's disease in a pediatric patient. (2010) (8)
- Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt (2021) (8)
- The Heart Age Is Increased in Patients With Nonalcoholic Fatty Liver Disease and Correlates With Fibrosis and Hepatocyte Ballooning (2016) (7)
- Accuracy of Noninvasive Fibrosis Scores in Predicting the Presence of Fibrosis in Patients after Liver Transplantation. (2018) (7)
- Designing Clinical Trials in Pediatric Nonalcoholic Steatohepatitis: Tips for Patient Selection and Appropriate Endpoints (2019) (7)
- Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma. (2020) (7)
- Long Term Complications in Pediatric Liver Transplant Recipients: What Every Pediatrician Should Know. (2016) (6)
- Endoscopic appearance of an esophageal squamous papilloma in a pediatric patient. (2008) (6)
- Diabetes Liver Fibrosis Score to Detect Advanced Fibrosis in Diabetics with Non-alcoholic Fatty Liver Disease. (2021) (6)
- Driving Nonalcoholic Steatohepatitis Forward Using the FibroScan Aspartate Aminotransferase Score, But Obey the Traffic Lights (2020) (6)
- Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients (2019) (6)
- Serum cytokeratin‐18 fragment levels predict development of type 2 diabetes mellitus in adult patients with NAFLD (2015) (6)
- Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 Diabetes (2021) (6)
- Accounting for the Placebo Effect and Optimizing Outcomes in Clinical Trials of Nonalcoholic Steatohepatitis (NASH) (2020) (6)
- Treatment of Recurrent Hepatitis C Genotype-4 Post-Liver Transplantation with Sofosbuvir plus Simeprevir (2015) (6)
- Safety and efficacy of combination therapies including cilofexor/ firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial (2020) (5)
- Non-alcoholic fatty liver disease: a pandemic disease with multisystem burden. (2018) (5)
- Low Utility of Noninvasive Fibrosis Scores in Young Adults with Nonalcoholic Fatty Liver Disease (2017) (5)
- A perspective on RNA interference-based therapeutics for metabolic liver diseases (2021) (5)
- Artificial Intelligence in Nonalcoholic Fatty Liver Disease: A New Frontier in Diagnosis and Treatment (2021) (5)
- Trends of Awareness of Non-Alcoholic Fatty Liver Disease, Alcoholic Liver Disease and Both Fatty Liver Diseases (BAFLD) Using National Health and Nutrition Examination Survey (2018) (5)
- Putting it all together: Noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in adults and children (2017) (5)
- Spur cell anemia as a cause of unconjugated hyperbilirubinemia after liver transplantation and its resolution after retransplantation (2011) (5)
- The use of omega-3 Fatty acids in nonalcoholic Fatty liver disease: the end of the road or a new beginning? (2015) (4)
- Survival outcomes scores (SOFT, BAR, and Pedi‐SOFT) are accurate in predicting post‐liver transplant survival in adolescents (2016) (4)
- The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database (2022) (4)
- Hereditary Hemorrhagic Telangiectasia With Liver Vascular Malformation Presenting With High-Output Heart Failure (2014) (4)
- Gastric Polyposis: A Rare Cause of Iron Deficiency Anemia in a Patient With Portal Hypertension (2015) (4)
- PS-111-Six month interim results of MSDC-0602 K in a large phase 2b NASH study demonstrate significant improvement in liver enzymes and glycemic control (NCT02784444) (2019) (4)
- Cholestasis in Benign Recurrent Intrahepatic Cholestasis 2 (2020) (4)
- Regular aspirin use is not protective against advanced fibrosis in type-2 diabetics with biopsy-proven nonalcoholic fatty liver disease (2018) (4)
- 383 Analysis of Breath Volatile Organic Compounds As a Noninvasive Tool to Diagnose Nonalcoholic Fatty Liver Disease in Obese Children (2013) (4)
- A Specific Breath Metabolome Signature Identifies Patients With Inflammatory Bowel Diseases: 1842 (2015) (4)
- Su1038 Liver Transplantation for Nonalcoholic Steatohepatitis (NASH) in Children and Young Adults: The True Burden of Pediatric Nonalcoholic Fatty Liver Disease (2015) (4)
- Hematocrit levels and red blood cell indices in patients with nonalcoholic fatty liver disease. (2014) (4)
- A practical use of noninvasive tests in clinical practice to identify high‐risk patients with nonalcoholic steatohepatitis (2022) (4)
- Anemia in Patients with Chronic Hepatitis C Infection during Triple Therapy with Telaprevir or Boceprevir - A Controlled Study (2013) (4)
- Analysis of Exhaled Volatile Organic Compounds Reveals New Biomarkers for Irritable Bowel Syndrome: ACG Fellow Award: 1827 (2014) (3)
- Cardiovascular risk in pediatric nonalcoholic fatty liver disease: recent advances (2015) (3)
- Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials (2022) (3)
- The successful use of telaprevir to treat hepatitis C recurrence after liver transplantation in an HIV co-infected patient. (2014) (3)
- FAMILIAL ADENOMATOUS POLYPOSIS IN CHILDREN: A CASE SERIES OF 13 PATIENTS (2006) (3)
- Performance of noninvasive tests of fibrosis among Asians, Hispanic and non-Hispanic Whites in the STELLAR trials. (2022) (3)
- Recurrent upper gastrointestinal bleeding masquerading as gastric variceal bleeding on endoscopy after liver transplantation (2013) (3)
- Characteristics and Outcomes of Liver Transplantation for Primary Biliary Cholangitis (PBC) in Young patients: Analysis of the United Network for Organ Sharing Database. (2019) (3)
- Liver Transplant in Young Adults with Chronic Hepatitis C Virus: An Argument for Hepatitis C Treatment in Childhood. (2016) (3)
- Trends in Prevalence of Nonalcoholic Fatty Liver Disease in US Adults with Prediabetes (2019) (3)
- Oligonucleotide‐Based Therapeutics: An Emerging Strategy for the Treatment of Chronic Liver Diseases (2020) (3)
- Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. (2022) (3)
- Association between anti-acid therapies and advanced fibrosis in type 2 diabetics with biopsy-proven non-alcoholic fatty liver disease (2020) (3)
- Disease state transition probabilities across the spectrum of NAFLD: A systematic review and meta-analysis of paired biopsy or imaging studies. (2022) (3)
- M1770 Serum Retinol-Binding Protein 4 (RBP4) Levels in Patients with Nonalcoholic Fatty Liver Disease (2008) (3)
- Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT) (2022) (3)
- Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017–2018 (2022) (3)
- Noninvasive measure of treatment response in non‐alcoholic steatohepatitis: Insights from EMMINENCE and meta‐analysis (2021) (3)
- Volatile Organic Compounds in the Exhaled Breath as Biomarkers of Nonalcoholic Steatohepatitis in Obese Children: 485 (2014) (2)
- Prevalence and risk factors of nonalcoholic fatty liver disease in metabolically healthy obese adolescents in the United States: an analysis of national health and nutrition examination survey data (2017) (2)
- Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development (2020) (2)
- 566 An Apoptosis Panel for Nonalcoholic Steatohepatitis Diagnosis (2009) (2)
- Increase in Alcoholic Hepatitis as an Etiology for Liver Transplantation in the United States: A 2004–2018 Analysis (2020) (2)
- MRI-AST Score Accurately Predicts Major Adverse Liver Outcome, Hepatocellular Carcinoma, Liver Transplant, and Liver-Related Death. (2023) (2)
- Commonly Used Hepatic Fibrosis Scores Have Poor Performance in Young Adult With Nonalcoholic Fatty Liver Disease: 2095 (2015) (2)
- Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease (2022) (2)
- Health Related Quality of Life in Children With Autoimmune Liver Disease (2011) (2)
- Primary data analyses of MAESTRO-NAFLD-1 a 52 week double-blind placebo-controlled phase 3 clinical trial of resmetirom in patients with NAFLD (2022) (2)
- Maintaining Patient Safety and Data Integrity of Nonalcoholic Steatohepatitis Clinical Trials During the Severe Acute Respiratory Syndrome–Coronavirus 2 Pandemic (2020) (2)
- Lower Rates of Hepatocellular Carcinoma Observed Among Cannabis Users: A Population-Based Study (2022) (2)
- A multistakeholder approach to innovations in NAFLD care (2023) (2)
- Sofosbuvir-Based Treatment Is Safe and Effective in Patients With Chronic Hepatitis C Infection and End-Stage Renal Disease: 2056 (2015) (2)
- LBP-18-Effect of Obeticholic Acid on Liver Function in Patients with Fibrosis due to NASH (2019) (2)
- Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD‐related cirrhosis (2022) (2)
- Mo1901 Evaluation of Portal Hypertension and Cirrhosis in Patients With Hepatic Sarcoidosis: A Prospective Single Center Study (2015) (2)
- Genetics and hepatitis C: It’s good to be ‘CC’ (2015) (2)
- MEFIB vs MAST and FAST: Not a competition but useful tools. (2022) (2)
- Nonalcoholic Fatty Liver Disease (2018) (2)
- Liver Transplantation for Hepatitis B in Early Adulthood: Analysis of the United Network for Organ Sharing Database. (2016) (1)
- S1054 Is Frailty Being Addressed in Our Pre-Transplant Cirrhotic Patients?: A Look at the Data (2020) (1)
- 946 The Increasing Burden of Nonalcoholic Fatty Liver Disease among Young Adults in the United States: A Growing Epidemic (2016) (1)
- 804 Nerve Growth Factor (NGF) - p75 Neurotrophin Receptor Axis Is Upregulated in Children With Nonalcoholic Steatohepatitis (2015) (1)
- Usefulness of Neutrophil to Lymphocyte Ratio in Predicting Steatohepatitis in Patients with Nonalcoholic Fatty Liver Disease: 297 (2010) (1)
- Hepatitis C treatment with triple therapy in a patient with hemophilia A. (2013) (1)
- SAT-006-Efficacy of oral thrombopoietin receptor agonist lusutrombopag in chronic liver disease by underlying disease aetiology (2019) (1)
- Shear wave elastography reveals a high prevalence of liver fibrosis in overweight or obese Hispanic youth (2020) (1)
- Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis (2018) (1)
- Mo1980 Metabolomic Analysis of Exhaled Breath to Identify Volatile Organic Compounds (VOCs) in Children With Inflammatory Bowel Disease (2013) (1)
- Characterization of Baseline Thrombopoietin Levels in Patients With Chronic Liver Disease: Results From 2 Pooled Clinical Studies in Patients With Thrombocytopenia and Liver Disease (2018) (1)
- Tu1723 Extrahepatic Complications Are Extremely Common in Children With Nonalcoholic Fatty Liver Disease (NAFLD) and Their Frequency Correlates With NAFLD Histologic Severity (2016) (1)
- Prevalence of nonalcoholic fatty liver disease in lean adolescents in the United States: an analysis of national health and nutrition examination survey data (2017) (1)
- Characterization of patients with Both Alcoholic and Nonalcoholic Fatty Liver Disease (BAFLD) in a large United States cohort (2018) (1)
- Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials (2019) (1)
- Treating nonalcoholic steatohepatitis in children: Not a cinch task (2017) (1)
- M1988 Noninvasive Markers of Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease (NAFLD) (2010) (1)
- 2942 Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH): AURORA Phase 3 Study Design (2019) (1)
- BMS-986263 (novel targeted lipid nanoparticle delivering HSP47 siRNA) safety and target engagement in patients with advanced hepatic fibrosis: week 36 results from a phase 2 randomized, double-blind, placebo-controlled trial (2020) (1)
- Biomarkers, imaging and safety in a well-compensated NASH cirrhotic cohort treated with resmetirom, a thyroid hormone receptor beta agonist, for 52 weeks (2022) (1)
- Efficacy of avatrombopag compared with placebo across various mean baseline platelet count subgroups- pooled data from 2 Phase 3 studies (2018) (1)
- Validity of Non-Invasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type 2 Diabetes With Suspected Non-Alcoholic Fatty Liver Disease: 2017 ACG Governors Award for Excellence in Clinical Research: 870 (2017) (1)
- Use of ledipasvir/sofosbuvir in patients with advanced chronic kidney disease (eGFR ≤ 30 mL/min): a case series (2017) (1)
- Maintaining Patient Safety and Data Integrity of NASH Clinical Trials During the SARS-CoV-2 Pandemic. (2020) (1)
- Su1468 - Superiority of Avatrombopag to Placebo in Increasing Platelet Counts and Reducing Platelet Transfusions in Patients with Chronic Liver Disease-Associated Thrombocytopenia Undergoing Scheduled Procedurespooled Analysis of 2 Randomized Phase 3 Studies (2018) (1)
- Multidisciplinary Approach for Liver Transplantation in Patients with Nonalcoholic Steatohepatitis: It Takes a Village (2020) (1)
- Response to Pellicano (2017) (1)
- Chronic Constipation Due to Delayed Diagnosis of a Congenital Anal Web (2012) (1)
- 1015 Fibroscan Is a Feasible and Useful Point-Of-Care Tool to Assess Nonalcoholic Fatty Liver Disease Severity in Children Texas Liver Institute, University of Texas (UT) Health San Antonio, San Antonio, TX (2019) (1)
- Liver Transplantation for Hepatocellular Carcinoma in Young Adults: A United Network for Organ Sharing Study. (2017) (1)
- IDDF2019-ABS-0131 Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials (2019) (1)
- Tu1553 - Efficacy of Avatrombopag Compared with Placebo Across Various Mean Baseline Platelet Count Subgroups-Pooled Data from 2 Phase 3 Studies (2018) (1)
- Reversal of Protein-Losing Enteropathy after Liver Transplantation in a Child with Idiopathic Familial Neonatal Hepatitis: 572 (2008) (1)
- IDDF2019-ABS-0133 Routinely available noninvasive tests discriminate advanced fibrosis due to NASH in the phase 3 STELLAR trials of the ASK1 inhibitor selonsertib (2019) (1)
- SAT-136-Hepatocellular carcinoma does not impact the efficacy of avatrombopag in increasing platelet counts and reducing platelet transfusions or rescue procedures for bleeding in chronic liver disease patients with thrombocytopenia (2019) (1)
- Hepatitis B Immunity and Response to Booster Immunization in Children With Inflammatory Bowel Disease Treated With Infliximab (2011) (1)
- Hepatitis C in children and adolescents: The good, the bad, and the ugly (2008) (1)
- Letter: volatile metabolomics of exhaled breath or faecal gas? – authors' reply (2015) (1)
- The Inflamed Liver and Atherosclerosis: A Link Between Histologic Severity of Nonalcoholic Fatty Liver Disease and Increased Cardiovascular Risk: 315 (2009) (1)
- Obesity, Inflammation, Nonalcoholic Fatty Liver Disease, and Hepatocellular Carcinoma (2013) (1)
- PC.01.9 EVALUATION OF OBETICHOLIC ACID EFFICACY IN PATIENTS WITH NASH WHO WERE MONITORED USING NONINVASIVE TESTS: A POST HOC ANALYSIS OF THE REGENERATE TRIAL (2021) (1)
- In reply: Acute liver failure (June 2016) (2016) (0)
- Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study. (2023) (0)
- 850 Low Serum Potassium Levels Are Associated With the Presence of Nonalcoholic Steatohepatitis and Fibrosis in Children With Nonalcoholic Fatty Liver Disease (2014) (0)
- Transjugular Intrahepatic Portosystemic Shunts (TIPS) in Elderly Patients: To TIPS or Not to TIPS?: 2031 (2014) (0)
- The use of current knowledge and non‐invasive testing modalities for predicting at‐risk non‐alcoholic steatohepatitis and assessing fibrosis (2023) (0)
- Lean NAFLD: Should it be considered in Lean Adolescents with Elevated Liver Enzymes? (2018) (0)
- SAT-272-A simple algorithm based on electronic medical records to identify NAFLD with advanced fibrosis in patients with Type 2 diabetes (2019) (0)
- Su1169 Analysis of Exhaled Breath Volatile Organic Compound Can Be Used to Differentiate Children With Celiac Disease From Healthy Controls (2016) (0)
- Simple diagnostic algorithm identifying at-risk nonalcoholic fatty liver disease patients needing specialty referral within the United States (2022) (0)
- Non-invasive test cut-offs for the identification of advanced liver fibrosis in a diabetes cohort with non-alcoholic steatohepatitis: data from the phase 3 AURORA study (2020) (0)
- Metabolic profiles and liver steatosis in children with liver transplantation for progressive familial intrahepatic cholestasis type 1 (2015) (0)
- A Non-Invasive Prediction Model for Non-Alcoholic Steatohepatitis (NASH) in Pediatric Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): 385 (2013) (0)
- Artificial Intelligence Applications in Hepatology. (2023) (0)
- Use of Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation in an HIV Co-infected Patient: 1210 (2013) (0)
- Screening for non-alcoholic fatty liver disease in persons with type 2 diabetes in the U.S. is cost effective: A comprehensive economical analysis (2020) (0)
- Mo1494 - Prevalence of Nonalcoholic Fatty Liver Disease in Lean Adolescents in the United States (2018) (0)
- Real World Experience With Vitamin E and Pentoxifylline for the Treatment of Nonalcoholic Steatohepatitis: 2007 (2015) (0)
- S1090 Exploring the Role of Choline and Phospholipids in Pediatric Nonalcoholic Fatty Liver Disease (2021) (0)
- Sa1886 - Association of Various Anti-Hypertensive Agents and Advanced Fibrosis in Type-2 Diabetics with Biopsy-Proven Nonalcoholic Fatty Liver Disease (2018) (0)
- Tu1695 HEALTH OUTCOMES OVER 6 MONTHS IN 907 PATIENTS WITH HEPATIC ENCEPHALOPATHY TREATED IN COMMUNITY PRACTICE USING A SPECIALIZED PHARMACY TEAM (2020) (0)
- Mo1981 Alanine Aminotransferase Values in Obese Children With Nonalcoholic Fatty Liver Disease Diagnosed With Liver Ultrasonography (2014) (0)
- 1295 A Unique BRIC Case With Response to Glucocorticoids (2019) (0)
- Indications and Outcomes of Transjugular Intrahepatic Portosystemic Shunts (TIPS) in Children and Young Adults With Portal Hypertension: 2057 (2015) (0)
- Accuracy of Noninvasive Fibrosis Scores in Predicting the Presence of Fibrosis in Patients After Liver Transplantation: Presidential Poster: 2096 (2015) (0)
- Su1282 A Novel Non-Invasive Breath Test in Patients With Acute Alcoholic Hepatitis (2013) (0)
- The development of the NAF3 score to accurately predict the presence of active NASH with advanced fibrosis (2020) (0)
- The Impact of Aspirin Use on Liver Histology in Patients With Nonalcoholic Fatty Liver Disease (NAFLD): 2135 (2015) (0)
- Mo1502 – The Association of Hepatocellular Carcinoma and Cannabis Use (2019) (0)
- Association of Anti-Tumor Necrosis Factor-a Agents and Advanced Fibrosis in Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (2018) (0)
- Challenges and opportunities in NASH drug development (2023) (0)
- Lean NAFLD (2018) (0)
- Tu1673 LONG-TERM SAFETY PROFILE OF CENICRIVIROC IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS: ROLLOVER STUDY (2020) (0)
- Effect of Hepatitis C Viremia on Posttransplant Diabetes Mellitus in Liver Transplant Recipients (2021) (0)
- Real Life Experience of Hepatitis C Treatment With a Combination of Sofosbuvir and Simeprevir: 645 (2014) (0)
- The accuracy of the fast score in predicting NASH with significant fibrosis (2020) (0)
- Mean Platelet Volume (MPV) as a Marker of Increased Cardiovascular Risk in Patients with Nonalcoholic Steatohepatitis: 271 (2011) (0)
- The Successful Use of Eltrombopag in the Treatment of Thrombocytopenia in Two Patients With Recurrent Hepatitis C After Liver Transplantation: 1290 (2014) (0)
- Effect of Telaprevir on the Pharmacokinetics of Tacrolimus in the Treatment of Hepatitis C After Liver Transplantation Presidential Poster: 429 (2012) (0)
- 640: THE PREVALENCE OF NONALCOHOLIC STEATOHEPATITIS (NASH) CIRRHOSIS IN THE UNITED STATES POPULATION: ANALYSIS OF THE NHANES 2017-2018 CYCLE (2022) (0)
- 366 Sofosbuvir and Simeprevir Effectively Treat Hepatitis C Virus Genotype 1 Infection After Liver Transplantation in a Multi-Center Experience (2015) (0)
- Role of Stearoyl-CoA Desaturase (SCD), Key Enzyme in Obesity, in Development of Human Hepatocellular Carcinoma (HCC): Is HCC Expected to Rise With Obesity Epidemic? (2013) (0)
- 1047 Changes in Liver Fibrosis Scores in Patients With New Onset Type 2 Diabetes on Triple Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy: Year Two Results (2019) (0)
- P0508 : Biopsy findings, ACE levels and APRI are similar in patients with sarcoidosis with and without portal hypertension (2015) (0)
- S1842 Hepatocyte Apoptosis in a Nutritional Model of Steatohepatitis in Ossabaw Miniature Swine (2010) (0)
- Prevalence of Fatty Liver Disease Post-Liver Transplantation and Its Relationship to Cardiovascular Events: 539 (2014) (0)
- The platelet count is declining in American adults in parallel with an increase in risk factors for nonalcoholic fatty liver disease (2018) (0)
- Tu1040 Safety and Efficacy of Sofosbuvir and Simeprevir to Treat Hepatitis C Virus Genotype 1 Infection in Decompensated Cirrhosis (2015) (0)
- Sa1635 – Factors Associated with Liver Transplantation in Type-2 Diabetics with Biopsy-Proven Non-Alcoholic Fatty Liver Disease (2019) (0)
- Biomarkers, Imaging, and Safety in a Well-compensated NASH Cirrhotic Cohort Treated With Resmetirom, a Thyroid Hormone Receptor-beta Selective Agonist, for 52 Weeks (2023) (0)
- SAT-273-Impact of age on routinely available non-invasive tests for the discrimination of advanced fibrosis due to NASH in the phase 3 STELLAR trials of the ASK1 inhibitor selonsertib (2019) (0)
- Under the Radar: Diagnosing Binge Eating Disorder in a Pediatric Obesity Clinic (2018) (0)
- S1187 External Validation of an MRI-Based Score to Predict the Presence of Fibrotic NASH (2021) (0)
- Favorable safety profile of TERN-201, a highly selective inhibitor of vascular adhesion protein-1, in the non-alcoholic steatohepatitis phase 1b AVIATION study (2022) (0)
- Serum Bilirubin Level Is Inversely Associated with Non-alcoholic Steatohepatitis in Children Presidential Poster: 1929 (2012) (0)
- Portal Vein Thrombosis Associated with Primary Cytomegalovirus Infection in an Immunocompetent Child: 1063 (2010) (0)
- Prevalence of Liver Cancer in Hereditary Hemochromatosis and Associated Outcomes: A Propensity-Matched Analysis (2021) (0)
- 933 Prospective Evaluation of the Combination of Markers of Hepatocyte Apoptosis and Oxidative Stress in Identifying Nonalcoholic Steatohepatitis (2012) (0)
- S3286 Identifying Patients With Metabolic Syndrome Who Require Pharmacotherapy for Nonalcoholic Steatohepatitis (NASH) Using the FAST Score (2020) (0)
- The Use of Tacrolimus in Refractory Autoimmune Hepatitis in Children and Adults: A Single-Center Experience: 792 (2016) (0)
- Sa1028 ABO Blood Groups and Risk of Major Adverse Cardiac Events Post Liver Transplant (2014) (0)
- Body Mass Index Does Not Impact the Efficacy of Avatrombopag in Increasing Platelet Counts and Reducing Platelet Transfusions or Rescue Procedures for Bleeding in Cirrhotic Patients with Thrombocytopenia: Presidential Poster Award (2018) (0)
- Su1070 Safety and Efficacy of Telaprevir-Based Triple Therapy to Treat HCV Recurrence Post-Liver Transplantation (2014) (0)
- Exploring the Role of Choline and Phospholipids in Pediatric Nonalcoholic Fatty Liver Disease (2021) (0)
- Sex differences in age at wait‐list registration for liver transplantation with nonalcoholic steatohepatitis as primary indication (2020) (0)
- A Case of too Much Love from the Liver: Hereditary Hemorrhagic Telangiectasia with Liver Vascular Malformation Presenting with High-output Heart Failure: 1076 (2012) (0)
- 994 The Performance of the NAFLD Fibrosis Score in Hispanics With Type 2 Diabetes and Biopsy-Proven NAFLD (2019) (0)
- S1858 Syphilis: The Rare Primary Biliary Cholangitis Mimic (2022) (0)
- Comparison between Retrograde Ileoscopy via Stoma and Small Bowel Imaging in Diagnosing Crohnʼs Disease Recurrence after Diverting Ileostomy: 1284 (2009) (0)
- Plasma Myeloperoxidase Levels Correlate with the Presence of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: 433 (2012) (0)
- 1148-P: Cenicriviroc Safety in over 1,200 Subjects (2019) (0)
- MRI assessment (cT1) with LiverMultiScan following VCTE improves the diagnostic yield for high-risk NASH (2022) (0)
- Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scores (2023) (0)
- Hospital Readmission After Transjugular Intrahepatic Portosystemic Shunts (TIPS): 2021 (2014) (0)
- P-150 Analysis of the Breath Metabolome for the Diagnosis and Differentiation of Inflammatory Bowel Disease: A Pilot Study (2013) (0)
- Pediatric cholestatic liver disease: Successful transition of care (2019) (0)
- Lack of reliability of liver biopsies in non-alcoholic steatohepatitis (NASH) clinical trials - potential implications for developing new therapies for NASH (2020) (0)
- Pharmacokinetic (PK) and pharmacodynamics (PD) of BIO89-100, a novel glycoPEGylated FGF21, in non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (2022) (0)
- SAT-135-Splenomegaly status does not impact the efficacy of avatrombopag in increasing platelet counts and reducing platelet transfusions or rescue procedures for bleeding in chronic liver disease patients with thrombocytopenia (2019) (0)
- 235 RIP3 Deficiency Enhances High Fat Diet-Induced Liver Injury and Hepatocyte Apoptosis in Mice (2015) (0)
- Serum Ceruloplasmin, Ferritin, and Their Ratio Are Significantly Associated With Nonalcoholic Steatohepatitis in Patients With NAFLD: 427 (2014) (0)
- Multiparametric MRI biomarker corrected T1 as a prognostic marker in chronic liver disease (2022) (0)
- Sa1047 The Real Life Experience With the Development and Management of Anemia in the Era of Protease Inhibitors for Chronic Hepatitis C Infection (2013) (0)
- 291 Monitoring Peripheral Blood CD4+ Adenosine Triphosphate (ATP) Activity in Orthotopic Liver Transplantation (OLT) Recipients with Hepatitis C Virus (HCV) Infection and Its Correlation to Fibrosis Progression (2009) (0)
- Accuracy of noninvasive fibrosis scores in predicting advanced fibrosis in pediatric patients after liver transplantation (2022) (0)
- Association of Smoking With Advanced Fibrosis in Type 2 Diabetics With Suspected Non-Alcoholic Fatty Liver Disease: 997 (2017) (0)
- 1456-P: Identifying Diabetic and Prediabetic Patients Who Require Pharmacotherapy for Nonalcoholic Steatohepatitis Using the FAST Score (2020) (0)
- 1014 RETINOL-BINDING PROTEIN 4: A PROMISING CIRCULATING MARKER OF LIVER DAMAGE IN CHILDREN WITH NONALCOHOLIC FATTY LIVER DISEASE (2009) (0)
- The Prevalence of Hepatitis A Antibodies in Children with Inflammatory Bowel Disease: 1463 (2010) (0)
- Development and Natural History of Anemia in Hepatitis C Patients Treated with Protease Inhibitors: 359 (2012) (0)
- 1146 The Use of Liver Biopsy to Determine the Severity of Nonalcoholic Fatty Liver Disease in Children Across the United States (2019) (0)
- S3248 Nutritional Evaluation of Pre-Transplant Patients With End-Stage Liver Disease (2020) (0)
- Tu1032 Sofosbuvir and Simeprevir Regimen to Treat Chronic Hepatitis C Infection in Patients With End-Stage Renal Disease (2015) (0)
- Screening of Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease: Are We Doing a Good Job?: 2049 (2015) (0)
- Estimating the prevalence of advanced fibrosis due to non-alcoholic fatty liver disease in the United States population (2022) (0)
- Post-Stomal Pyoderma Gangrenosum-a Rare Extraintestinal Manifestation of Crohnʼs Disease in a Pediatric Patient: 855 (2008) (0)
- Long-term safety profile of cenicriviroc in adults with non-alcoholic steatohepatitis: rollover study (2020) (0)
- Portal Hypertensive Gastric Polyps Presenting as Iron Deficiency Anemia in a Cirrhotic Patient: 1225 (2014) (0)
- Mo1006 Alanine Aminotransferase (ALT) to Triglyceride (TG) Ratio As a Marker of Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Children (2013) (0)
- The development of the diabetes liver fibrosis score: A new prediction model to detect advanced fibrosis in diabetics with nonalcoholic fatty liver disease (2018) (0)
- What happened to liver health in patients with chronic liver disease during the COVID19 pandemic (2021) (0)
- Tu1721 Reduced Lysosomal Acid Lipase Activity - A Potential Role in the Pathogenesis of Non Alcoholic Fatty Liver Disease in Pediatric Patients? (2016) (0)
- An unusual cause of right lower quadrant pain. (2009) (0)
- S1067 A Retrospective Review: Are We Adequately Screening for Important Outcome Predictors in Pre-Transplant Cirrhotic Patients? (2020) (0)
- 76 – Portal Hypertension (2011) (0)
- When Hepatitis B Serology Lies: Misleading Hepatitis B Testing Prior to Starting Immunosuppressive Therapy Due to Recent Vaccination and Intravenous Immunoglobulin Infusion: 2014 (2015) (0)
- Prevalence of at-risk NASH and its association with metabolic syndrome in US adults with NAFLD, 2017–2018 (2023) (0)
- Obeticholic Acid Efficacy in Patients With NASH Monitored Using Noninvasive Tests: Post Hoc Analysis of REGENERATE Trial (2021) (0)
- THU-292-The natural history of NASH-induced advanced fibrosis in a large cohort of patients with type-2 diabetes (2019) (0)
- 902 Isoprene in the Exhaled Breath Is a Novel Biomarker for Advanced Fibrosis in Patients With Chronic Liver Disease (2015) (0)
- Sa1659 The Validation of Trimethylamine (TMA) as a Novel Breath Biomarker that Identifies Patients With Alcoholic Hepatitis (2016) (0)
- Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in type-2 diabetic patients via non-invasive methods (2017) (0)
- Drug Development for the Management of Nonalcoholic Steatohepatitis Cirrhosis. (2021) (0)
- Utility of FIB-4 thresholds to identify patients with at-risk F2-F3 NASH based on screening data from a 2000 patient biopsy confirmed cohort of resmetirom Phase 3 clinical trial, MAESTRO-NASH (2022) (0)
- Use of non-invasive methods to assess hepatic steatosis and advanced fibrosis in type-1 diabetic patients (2017) (0)
- Su1806 Markers of Macrophage Activation and Survival Correlate With the Presence of Advanced Fibrosis in Patients With Nonalcoholic Fatty Liver Disease (2015) (0)
- Serum Cytokeratin-18 Fragment Levels Predict Development of Type 2 Diabetes Mellitus in Adult Patients With Nonalcoholic Fatty Liver Disease: 472 (2014) (0)
- The Relationship of Steatosis Grade, Zone and Type to Key Histological Features in Children with Nonalcoholic Fatty Liver Disease: 1451 (2009) (0)
- Baseline demographics and clinical characteristics of subjects enrolled in the phase 3 AURORA study of cenicriviroc for the treatment of liver fibrosis associated with non-alcoholic steatohepatitis (2020) (0)
- Lean Nonalcoholic Fatty Liver Disease: Should It Be Considered in Lean Adolescents With Elevated Liver Enzymes? (2019) (0)
- Analysis of Volatile Organic Compounds in the Exhaled Breath of Patients with Celiac Disease (2015) (0)
- Alpha-1 Antitrypsin Deficiency and the Risk of Hepatocellular Carcinoma in Patients With End-Stage Liver Disease: 459 (2014) (0)
- Mo1383: SEQUENTIAL TESTING FOR HIGH-RISK NASH BY CT1 FROM LIVERMULTISCAN IMPROVES DIAGNOSTIC YIELD COMPARED TO THE USE OF MRE ALONE (2022) (0)
- SAT-298-MR elastography based fibrosis correlates with clinical liver events in patients with non-alcoholic fatty liver disease: A multi-center study (2019) (0)
- Telaprevir-Based Triple Therapy of Hepatitis C Infection in a Patient with Hemophilia A and Factor VIII Inhibitor: Decreased Need for Factor VIII with Viral Suppression: 1069 (2012) (0)
- 1027 Health Outcomes in Patients With Hepatic Encephalopathy Treated in Community Practice Using a Specialized Pharmacy Team (2019) (0)
- Sofosbuvir Plus Simeprevir for the Treatment of Recurrent Hepatitis C With Fibrosing Cholestatic Hepatitis After Liver Transplantation: ACG Clinical Vignette Award Presidential Poster: 1261 (2014) (0)
- Transient Hepatitis B Surface Antigenemia Due to Recent Vaccination: 411 (2014) (0)
- T1614 Adipocyte Apoptosis: A Link Between Obesity, Insulin Resistance and Hepatic Steatosis (2009) (0)
- Tu1311: EXTERNAL VALIDATION OF THE AGILE3+ SCORE AS A PREDICTOR OF ADVANCED FIBROSIS IN A COHORT OF U.S. ADULTS WITH BIOPSYPROVEN NAFLD (2022) (0)
- Su1554 - The Effects of Oral Hypoglycemic Medications and Insulin Therapy on Advanced Fibrosis in Type-2 Diabetics with Biopsy-Proven Nonalcoholic Fatty Liver Disease (2018) (0)
- S1186 Evaluation of the FAST Score as a Predictor of Fibrotic NASH in Hispanics (2021) (0)
- The MRI and AST (MAST) score is correlated with noninvasive and histologic markers of fibrosis in patients with advanced fibrosis due to NASH (2022) (0)
- Liver Transplantation in Young Adults With Chronic Hepatitis HCV: An Argument for Hepatitis C Treatment in Childhood: 2006 (2015) (0)
- S1024 Evaluation of the FAST Score in Patients With Nonalcoholic Fatty Liver Disease and High Liver Stiffness Measurements (2020) (0)
- A Heavy Price for Weight Loss Supplements: Herbalife Related Acute Hepatitis: 1094 (2012) (0)
- 591 Obese Pediatric Patients Have Increased Cardiovascular Disease Risk Comparable to Pediatric Patients With Familial Dyslipidemia (2012) (0)
- Su1432 High Efficacy of Sofosbuvir/ Ledipasvir Without Ribavirin in Patients With HCV Recurrence After Liver Transplantation (2016) (0)
- Risk Factors Associated with Crohnʼs Disease Recurrence in Neo-Terminal Ileum after Diverting Ileostomy: 1140 (2008) (0)
- S1400 The Complexity of NASH Cirrhosis Clinical Trials: Screen Failure Reasons and Baseline Patient Characteristics (2022) (0)
- 1014 The Majority of Patients With Primary Biliary Cholangitits Do Not Achieve the Ideal Treatment Response in a Real World Clinical Practice (2019) (0)
- Aldafermin rebalances collagen turnover in patients with NASH and liver fibrosis in the ALPINE 2/3 study (2022) (0)
- 136-OR: Efficacy of Cenicriviroc (CVC) in Adults with NASH-Induced Liver Fibrosis (2019) (0)
- S1200 No Direct Impact of the COVID-19 Pandemic on the Prevalence of Steatosis and Fibrosis in Subjects With Suspected NAFLD (2021) (0)
- The association between perceived stress, acculturation, and non-alcoholic fatty liver disease in Mexican-origin adults in Southern Arizona (2023) (0)
- Analysis of Breath Volatile Organic Compounds to Assess the Severity of Non-Alcoholic Fatty Liver Disease: 886 (2017) (0)
- 1026 High SVR Rates in HCV-Infected Patients With Multiple Co-Morbid Medical Conditions Treated With HCV DAAs in Community Practice Using a Specialized Pharmacy Team (2019) (0)
- T1009 Severity of Liver Injury and Cardiovascular Risk in Children with Nonalcoholic Fatty Liver Disease (2009) (0)
- Response to: Retinol-binding Protein 4 Concentrations in Nonalcoholic Fatty Liver Disease (2010) (0)
- Pegozafermin led to significant metabolic benefits, in addition to robust beneficial effects on the liver, in an open-label cohort of a Phase 1b/2a study in subjects with non-alcoholic steatohepatitis (NASH) (2022) (0)
- Sa1632 Liver Transplantation Indications and Outcomes in Young Adults in the United States (2016) (0)
- Assessment of the prevalence of non-alcoholic fatty liver disease, its severity, and comorbidities in lean americans: national health and nutrition examination surveys (NHANES) with transient elastography assessment from 2017 to 2018 (2022) (0)
- Su1291 A Selective Breath Metabolome Signature Accurately Differentiates Inflammatory Bowel Disease Patients From Healthy Subjects (2014) (0)
- CD4+ T-Lymphocyte Adenosine Tri-Phosphate(ATP) Levels in Pediatric Patients with Crohnʼs Disease: A New Marker for Disease Activity: 1173 (2009) (0)
- 231 - Dyslipidemia Treatment and Advanced Fibrosis in Type-2 Diabetics with Biopsy-Proven Nonalcoholic Fatty Liver Disease (2018) (0)
- Tu2026 Characterization of Hepatocellular Carcinoma (HCC) in NAFLD Patients Without Cirrhosis (2015) (0)
- Gut Flora in the Development and Progression of Nonalcoholic Fatty Liver Disease (2016) (0)
- 827 Prevalence of Nonalcoholic Steatohepatitis-Induced Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data (2016) (0)
- Tu1565 – Clinical Utility and Application of Noninvasive Tests of Fibrosis in the Selection of Patients with Advanced Fibrosis Due to Nash in the Phase 2 Atlas Trial (2019) (0)
- 944 Outcome of Liver Transplantation in Children With Hepatopulmonary Syndrome - A Retrospective Analysis of the UNOS Database (2016) (0)
- Effects of Dietary Intervention on Breath Volatile Organic Compounds in Obese Children With Hypercholesterolemia: 2012 (2014) (0)
- The Hepatic Steatosis Index Is Not Accurate in Predicting the Presence of Fatty Liver Disease in Patients With Hepatitis C Who Achieve Sustained Virologic Response (2018) (0)
- THU-311-Liver enzymes cut offs in patients with advanced non-alcoholic fatty liver disease: A multi-center study (2019) (0)
- Obstructive Jaundice Associated with Situs Inversus, Polysplenia, Biliary Atresia, Intestinal Malrotation and Immotile Cilia Syndrome: 1456 (2009) (0)
- Spur Cell Anemia as a Cause of Unconjugated Hyperbilirubinemia and Its Resolution After Liver Transplantation: 801 (2009) (0)
- SAT-315-Clinical utility and application of non-invasive tests of fibrosis in the selection of patients with advanced fibrosis due to NASH in the Phase 2 ATLAS trial (2019) (0)
- Su1477 The Role of Transjugular Intrahepatic Portosystemic Shunt in the Management of Obscure Gastrointestinal Bleeding in Patients With Portal Hypertension (2014) (0)
- 1848-P: Insulin Sensitivity and Metabolic Profile of Subjects with Type 2 Diabetes and Nonalcoholic Steatohepatitis after Exposure to Cenicriviroc: A Subanalysis of the CENTAUR Study (2020) (0)
- Breath Biomarkers in Children with Chronic Liver Disease Compared to Healthy Controls: 411 (2013) (0)
- Clinical Features and Outcomes of Crohnʼs Disease of the Ileal Pouch in Pediatric Patients: 1464 (2009) (0)
- Plasma Cytokeratin-18 (CK18) Level As a Novel Biomarker for Predicting the Presence of Liver Fibrosis in Children with Nonalcoholic Fatty Liver Disease (NAFLD) (2015) (0)
- S1025 The Effects of Age on the Accuracy of the FAST Score to Predict the Presence of NASH With Significant Fibrosis (2020) (0)
- The Impact of Hyponatremia on the Outcomes of Wait-Listed and Transplanted Patients With Liver Cirrhosis: 632 (2014) (0)
- 184-OR: Liver Fibrosis Scores Do Not Predict Response to Therapy in T2DM (2020) (0)
- Portal Hypertension Complications Are Frequently the First Presentation of NAFLD in Patients Undergoing Liver Transplantation Evaluation: 2010 (2015) (0)
- Hepatitis B Virus Immunity in Pediatric Patients on Biologics for Inflammatory Bowel Disease: Results of a Prospective Cross-Sectional Study: 1462 (2010) (0)
- Feasibility and utility of controlled attenuation parameter and transient elastography in the assessment of nonalcoholic fatty liver disease severity in children (2018) (0)
- Tu1703 Exhaled Isoprene and Other Noninvasive Fibrosis Scores for Predicting Advanced Liver Fibrosis (2016) (0)
- Usefulness of neutrophil to lymphocyte ratio in fatty liver disease: authors' reply (2012) (0)
- Analysis of the breath metabolome in patients with Hepatocellular carcinoma (2017) (0)
- 2436 Lysosomal Acid Lipase Deficiency: A Missed Diagnosis Spanning All Ages (2019) (0)
- Triple Therapy with Exenatide/Pioglitazone/Metformin vs. Conventional Therapy: Changes in Liver Fibrosis Scores after 2 Years of Treatment in Patients with New-Onset Type 2 Diabetes Mellitus (2020) (0)
- 1164-P: Effects of Cenicriviroc in Adults with NASH on Inflammatory Cytokines and Metabolic Parameters (2019) (0)
- Tu1556 – Trends of Liver Transplant Indications Amongst Different Age Groups in United States (2019) (0)
- Mo1560 The Heart Age Is Increased in Patients With Nonalcoholic Fatty Liver Disease and Correlates With Fibrosis and Hepatocyte Ballooning (2016) (0)
- Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the Disease at the Metabolic Root (2020) (0)
- 40 The Development of the Pediatric NAFLD Fibrosis Score (PNFS) to Predict the Presence of Advanced Fibrosis in Children With Nonalcoholic Fatty Liver Disease (2014) (0)
- S1190 Identifying Patients With Type 2 Diabetes Mellitus Who Require Pharmacotherapy for Nonalcoholic Steatohepatitis (NASH) Using the FAST Score (2020) (0)
- Correlation Between Nonalcoholic Fatty Liver Disease Categories Defined by the NAFLD Activity Score and Pathologistʼs Diagnosis: 349 (2009) (0)
- Mo1320 Prevalence of Extrahepatic Complications of Nonalcoholic Fatty Liver Disease in Children (2015) (0)
- 125 Breathprints of Childhood Obesity: Changes in Volatile Organic Compounds in Obese Children and Adolescents Compared to Healthy Controls (2013) (0)
- Pegozafermin improved liver histology, liver-related non-invasive tests (NITs) and metabolic profiles in an open-label cohort of a Phase 1b/2a study in subjects with non-alcoholic steatohepatitis (NASH) (2022) (0)
- Transjugular Intrahepatic Portosystemic Shunt (TIPS) is a Feasible Option for Management of Portal Hypertension in Pediatric Liver Transplant Recipients: 1401 (2012) (0)
- Autoimmune Pancreatitis Associated with Autoimmune Hepatitis and Ulcerative Colitis in a Pediatric Patient: 515 (2010) (0)
- Sa1537 HIGH SVR RATES IN 1612 PATIENTS WITH MULTIPLE COMORBID MEDICAL CONDITIONS, INCLUDING ESRD, TREATED WITH HCV DAAS IN COMMUNITY PRACTICE USING A SPECIALIZED PHARMACY TEAM (2020) (0)
- The Prevalence of Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease Seen in Primary Care Setting: 799 (2016) (0)
- Liver transplantion for young adult hepatocellular carcinoma. (2016) (0)
- Mo1471 CHANGES IN TRENDS FOR LIVER TRANSPLANT IN PATIENTS OLDER THAN 70 IN THE UNITED STATES (2020) (0)
- M1989 Utility of the NAFLD Activity Score for Nonalcoholic Fatty Liver Disease Classification (2010) (0)
- M1990 Increasing the Yield of Liver Biopsy in Patients With Suspected Nonalcoholic Fatty Liver Disease (2010) (0)
- Both Alcoholic and Nonalcoholic Steatohepatitis Is an Emerging Indication for Liver Transplantation in the United States (2020) (0)
- Breath Analysis in Children with Ketogenic Glycogen Storage Diseases Presidential Poster Award (2018) (0)
- Elbasvir/grazoprevir in children aged 3–18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study (2023) (0)
- Sa1587 – Ethnic Disparities in the Outcomes of Liver Transplantation for Non-Alcoholic Steatohepatitis (2019) (0)
- PF702 USE OF THE THROMBOPOIETIN RECEPTOR AGONIST LUSUTROMBOPAG FOR THROMBOCYTOPENIA IN PATIENTS WITH HEPATOCELLULAR CARCINOMA UNDERGOING PLANNED INVASIVE PROCEDURES: INTEGRATED ANALYSIS OF 2 TRIALS (2019) (0)
- Mo1196 Lysosomal Acid Lipase Activity in Dried Blood Spots Correlates With the Severity of Hepatic Steatosis and Features of the Metabolic Syndrome in Children (2015) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Naim Alkhouri?
Naim Alkhouri is affiliated with the following schools:
